Skip to main content
Sandra Zeidler and Dr. Christine Wuebben (from left to right) from Bonn at the Pitch4Med Contest at the Heinrich Heine University Düsseldorf

Honors & Funding

ImmunoSensation entrepreneurs successfully pitch an innovative approach to fight respiratory viruses with an immunostimulatory nasal spray

A team of researchers in the group of Gunther Hartmann at the Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, and the Cluster of Excellence ImmunoSensation2 successfully pitched their start-up idea of Coldex, a nasal spray that provides protection from viral infections, at the Pitch4Med Contest at the Heinrich Heine University Düsseldorf and the 2nd Medical Pitch Contest of the Medical Faculty, University of Bonn. 

At the Pitch4Med Contest in Düsseldorf in October 2023, Dr. Christine Wuebben and her co-entrepreneurs first presented their innovative idea in a ten-minute pitch in front of a top-class jury consisting of Dr. Jan Engels, Investment Manager High-Tech Gründerfonds, Rolf Fellmann, Chairman of the business angel network Angel Engine and Lars Gussen, Investment Manager TechVision Fond, who gave the young researchers valuable feedback.

The Coldex team then entered the 2nd Medical Pitch Contest during the MIB Future Panel at the Medical Faculty Bonn with a refined five-minutes pitch. The distinguished jury, consisting of Dr. Laura Pedroza (Investment Manager, Hightech Gründerfonds), Dr. Christopher Jahn (Investment Manager, TechVision Fonds), Maximilian Erb (VC Department, NRW.Bank) and Dr. Alexander Zink (Head of Technology & Innovation, Xlife Sciences) was convinced by the innovative concept and awarded Coldex the shared first place in the competition.

Thanks to its promising approach, the Coldex team recently received prototyping grants from the transfer center enacom of the University of Bonn.

Related news

Kerstin Ludwig

Honors & Funding

Genome data to improve diagnosis and treatment of long Covid

—Despite the many advances, there are still major gaps in the care of patients with long-term and post-COVID. The Institute of Human Genetics at the UKB in Bonn now begins a genomLC study as part of a BMG funding priority. The researchers want to help speed up the diagnosis of long- and post-COVID and identify possible biomarkers that could possibly also differentiate between subgroups of the diseases. To this end, the genomic data of those affected is being analyzed as part of a study using blood samples. The project is funded by the Federal Ministry of Health (BMG) with 1.34 million euros.
View entry
Reckzeh News

Honors & Funding

Creating Personalized Cancer Treatments

—Bonn researchers aim to improve colon cancer treatment using 3D organoids and digital twins. Funded by the Federal Ministry of Education and Research (BMBF), a collaborative project involving the University of Bonn, the company ESQlabs and the University Hospital Bonn is seeking to refine the therapy recommendations given to colon cancer patients. To this end, “ISPOT-K” is merging organoids taken from patients with the power of digital twin technology.
View entry
Prof. Dr. Valentin Schäfer

Honors & Funding

Valentin Schäfer appointed to Specialized Ethics Committee

—Prof. Valentin S. Schäfer, Head of the Section of Rheumatology at the University Hospital Bonn (UKB) and researcher at the University of Bonn, has been appointed to the newly created Specialized Ethics Committee for Special Procedures by State Secretary Dr. Thomas Steffen at the Federal Ministry of Health. The committee, which is based at the Federal Institute for Drugs and Medical Devices (BfArM), will begin its work on July 1, 2025 and is responsible for the ethical evaluation of complex clinical trials.
View entry

Back to the news overview